Sustaita-Núñez VS, Donohue-Cornejo A, Cruz-Pérez IA, Villanueva-Sánchez FG, Trejo-Remigio DA, Jacinto-Alemán LF

Language: Spanish
References: 19
Page: 133-138
PDF size: 268.80 Kb.

ABSTRACT

Introduction: metalloproteinases are enzymes involved in tissue remodeling and their function is related to physiological and pathological processes, such as invasion and metastasis. These enzymes are capable of degrading components of the extracellular matrix, which may promote tumor progression. Conventional ameloblastoma (CA) is described as a benign intraosseous epithelial odontogenic neoplasm characterized by a slow and locally invasive progression, whose growth has been linked to bone turnover and extracellular matrix remodeling. The aim of the present work was to determine the immunohistochemical presence of MMP-1, MMP-2 and MMP-9 in CA. Material and methods: an analytical observational pilot study was performed using 5 CA, randomly collected from the archive of the Department of Oral and Maxillofacial Pathology, Escuela Nacional de Estudios Superiores (ENES) Unidad León, UNAM. The control group used were two dental follicle samples, obtained from patients with extraction indication for orthodontic treatment. The peroxidase immunohistochemistry assay was performed, collecting semiquantitatively level and proportion of immunoexpression. Results: four patients were male and one female, the average age was 40.6 ± 14.9 years. All specimens were obtained from the posterior mandibular region. Two specimens were observed with follicular pattern and three with plexiform pattern. MMP-2 and MMP-9 were detected only in one of the five specimens, with presence in the parenchyma of the lesion, with a proportion of 100% of the cell analyzed. Conclusion: according to our immunohistochemical analysis, MMP-2 and MMP-9 are the metalloproteinases that presented positive expression within the pathogenesis of CA compared to MMP-1; however, it is necessary to perform this type of studies in a larger population.

REFERENCES

1. Muller S, Vered M. Odontogenic and maxillofacial bone tumours. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. WHO classification of head and neck tumours. International Agency for Research on Cancer. 4th ed. IARC; 2017. pp. 215-219.

2. Waldron CA. Odontogenic cysts and tumors. In. Neville BW, Damm DD, Allen CM, Bouquot JE. Oral and maxillofacial pathology. 2nd ed. London, England: W B Saunders; 2002. pp. 611-618.

3. Sapp JP. Tumores odontógenos. Patología Oral y Maxilofacial Contemporánea. 2a ed. Elsevier; 2005, pp. 128-132.

4. Regezi JA, Sciubba JJ, Gómez JP. Tumores odontogénicos. Patología bucal?: correlaciones clinicopatológicas. 3a ed. McGraw-Hill Interamericana; 2000. pp. 327-338.

5. Mendonca RP, Balbinot KM, Martins BV, da Silva Kataoka MS, Mesquita RA, de Jesus Viana Pinheiro J, et al. Hypoxia and proangiogenic proteins in human ameloblastoma. Sci Rep. 2020; 10 (1): 17567.

6. Michalczyk K, Cymbaluk-Ploska A. Metalloproteinases in endometrial cancer-are they worth measuring? Int J Mol Sci. 2021; 22 (22): 12472.

7. Raeeszadeh-Sarmazdeh M, Do LD, Hritz BG. Metalloproteinases and their inhibitors: potential for the development of new therapeutics. Cells. 2020; 9 (5): 1313.

8. Ameli F, Ghafourina Nassab F, Masir N, Kahtib F. Tumor-derived matrix metalloproteinase-13 (MMP-13) expression in benign and malignant breast lesions. Asian Pac J Cancer Prev. 2021; 22 (8): 2603-2609.

9. Niland S, Riscanevo AX, Eble JA. Matrix metalloproteinases shape the tumor microenvironment in cancer progression. Int J Mol Sci. 2021; 23 (1): 146.

10. Zhang B, Cao X, Liu Y, Cao W, Zhang F, Zhang S et al. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer. 2008; 8 (1): 83.

11. Masson V, de la Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J. 2005; 19 (2): 234-236.

12. Shantha Kumara H, Miyagaki H, Herath SA, Pettke E, Yan X, Cekic V et al. Plasma MMP-2 and MMP-7 levels are elevated first month after surgery and may promote growth of residual metastases. World J Gastrointest Oncol. 2021; 13 (8): 879-892.

13. Matos LL, Stabenow E, Tavares MR, Ferraz AR, Capelozzi VL, Pinhal MA. Immunohistochemistry quantification by a digital computer-assisted method compared to semiquantitative analysis. Clinics (Sao Paulo). 2006; 61 (5): 417-424.

14. Farias LC, Gomes CC, Rodrigues MC, de Castro WH, Lacerda JCT, E Ferreira EF et al. Epigenetic regulation of matrix metalloproteinase expression in ameloblastoma. BMC Clin Pathol. 2012; 12 (1): 11.

15. Neagu D, Escuder-de la Torre O, Vázquez-Mahía I, Carral-Roura N, Rubín-Roger G, Penedo-Vázquez Á et al. Surgical management of ameloblastoma. Review of literature. J Clin Exp Dent. 2019; 11 (1): e70-75.

16. Zhang J, Gu Z, Jiang L, Zhao J, Tian M, Zhou J et al. Ameloblastoma in children and adolescents. Br J Oral Maxillofac Surg. 2010; 48 (7): 549-554.

17. Palanisamy JC, Jenzer AC. Ameloblastoma. En: StatPearls. StatPearls Publishing; 2022.

18. Frieling JS, Li T, Tauro M, Lynch CC. Prostate cancer-derived MMP-3 controls intrinsic cell growth and extrinsic angiogenesis. Neoplasia. 2020; 22 (10): 511-521.

19. Santos ES, Rodrigues-Fernandes CI, Cabral JC, Fonseca FP, Leme AFP. Epigenetic alterations in ameloblastomas: a literature review. J Clin Exp Dent. 2021; 13 (3): e295-302.